ShareThis Page

Pittsburgh-based ALung Technologies gets $12M in funding for artificial lung trial

| Friday, Feb. 19, 2016, 12:06 a.m.

ALung Technologies Inc. secured $12 million from investors as the South Side-based medical device company works toward U.S. regulatory approval of its artificial lung.

The company, which has been selling its device in Europe since 2014, plans to start a U.S. clinical trial next year with the aim of receiving Food and Drug Administration clearance by late 2018 or early 2019, CEO Peter DeComo said.

DeComo, who has led ALung since 2009, said the money was raised mostly from wealthy individuals in Western Pennsylvania rather than large venture capital firms, which have pulled back funding for medical devices since the financial crisis of 2008.

“It is extremely difficult to raise money for medical device development,” DeComo said. “We're very grateful to our investors.”

DeComo declined to say how much money ALung has raised from investors to date.

One of the company's benefactors was Eagle Ventures, a Shadyside investment firm, that has taken stakes in several medical technology firms in the Pittsburgh region.

“I'm very thrilled to have participated not only in a local successful financing, but one that truly is making a significant difference in the lives of people,” said Mel Pirchesky, Eagle Venture's president.

ALung's product, Hemolung RAS, removes carbon dioxide and delivers oxygen to the blood, allowing a patient in respiratory distress to avoid a ventilator or limit time on a ventilator, which can hurt lung tissue over time.

“Ventilators save lives, but they also damage lungs,” DeComo said.

Hemolung has been approved for use in Europe, Canada and Australia, and ALung is selling it in 17 countries.

It has been used in several U.S. hospitals, including UPMC facilities in Pittsburgh, under an FDA regulation that allows physicians to use unapproved devices in life-threatening situations where there are no other alternatives.

“In all those cases, the outcomes for those patients was very good,” DeComo said.

ALung, which employs 22 workers in Pittsburgh and six in Europe, also will use some of the money from its latest fundraising for product development, he said. The company wants to continue making the device more efficient, as well as create portable and wearable versions. Hemolung is currently available only as a large device that must remain in a hospital.

“And that could save significant costs to the system, by helping patients avoid going into the hospital,” Pirchesky said.

Alex Nixon is a Tribune-Review staff writer. Reach him at 412-320-7928 or

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.